FATE vs OGN · rev $13.6M vs P/E 3.4, rev $6.40B
Fate Therapeutics Inc (FATE) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
Fate Therapeutics Inc (FATE) is a biotechnology company listed on US.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Latest reported FATE revenue for 2024-12-31 was $13.6M. Net income was -$186.3M. Revenue was down 78.5% from 2023-12-31 to 2024-12-31. FATE currently screens at market cap $331.0M.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
FATE currently screens at market cap $331.0M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the FATE and OGN stock pages for the full models.
Not investment advice.